CN101172155A - 生脉温胆汤新剂型及其生产方法 - Google Patents
生脉温胆汤新剂型及其生产方法 Download PDFInfo
- Publication number
- CN101172155A CN101172155A CNA2006101231244A CN200610123124A CN101172155A CN 101172155 A CN101172155 A CN 101172155A CN A2006101231244 A CNA2006101231244 A CN A2006101231244A CN 200610123124 A CN200610123124 A CN 200610123124A CN 101172155 A CN101172155 A CN 101172155A
- Authority
- CN
- China
- Prior art keywords
- activating
- pulse
- gallbladder
- warming soup
- gallbladder warming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010792 warming Methods 0.000 title claims abstract description 107
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000009472 formulation Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 75
- 238000002360 preparation method Methods 0.000 claims abstract description 43
- 238000005516 engineering process Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 210000000232 gallbladder Anatomy 0.000 claims description 102
- 235000014347 soups Nutrition 0.000 claims description 100
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000002552 dosage form Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 28
- 241000244155 Taenia Species 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 230000002421 anti-septic effect Effects 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- -1 collecting decoction Substances 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- KWKVAGQCDSHWFK-VNKDHWASSA-N Methyl sorbate Chemical compound COC(=O)\C=C\C=C\C KWKVAGQCDSHWFK-VNKDHWASSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000001559 benzoic acids Chemical class 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 12
- 230000001502 supplementing effect Effects 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 7
- 235000013399 edible fruits Nutrition 0.000 abstract description 5
- 240000006079 Schisandra chinensis Species 0.000 abstract description 4
- 206010007625 cardiogenic shock Diseases 0.000 abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 4
- 230000002861 ventricular Effects 0.000 abstract description 4
- 244000183685 Citrus aurantium Species 0.000 abstract description 3
- 235000007716 Citrus aurantium Nutrition 0.000 abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 3
- 235000008599 Poria cocos Nutrition 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract description 2
- 235000017491 Bambusa tulda Nutrition 0.000 abstract description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract description 2
- 241001522129 Pinellia Species 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- 239000011425 bamboo Substances 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 abstract 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 38
- 239000000047 product Substances 0.000 description 30
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 238000011161 development Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 206010047470 viral myocarditis Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- 241000209128 Bambusa Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AXVZFRBSCNEKPQ-UHFFFAOYSA-N N-methyltyramine Chemical compound CNCCC1=CC=C(O)C=C1 AXVZFRBSCNEKPQ-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- OZWDYLLMBFLSNH-UHFFFAOYSA-N Swertisin Natural products COc1cc2OC(=CC(=O)c2c(O)c1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 OZWDYLLMBFLSNH-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- ABRULANJVVJLFI-DGHBBABESA-N swertisin Chemical compound COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ABRULANJVVJLFI-DGHBBABESA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VDULMXJUOWIPGE-UHFFFAOYSA-N 1-phenylisoquinoline quinoline Chemical compound N1=CC=CC2=CC=CC=C12.C1(=CC=CC=C1)C1=NC=CC2=CC=CC=C12 VDULMXJUOWIPGE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000218454 Bambusa tulda Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- FYSHYFPJBONYCQ-OLZOCXBDSA-N Gomisin K3 Natural products O(C)c1c(OC)c2-c3c(O)c(OC)c(OC)cc3C[C@@H](C)[C@@H](C)Cc2cc1OC FYSHYFPJBONYCQ-OLZOCXBDSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- BVGNIAWOQSCZOZ-UHFFFAOYSA-N N-methyl-zizyphine-B Natural products C1=CNC(=O)C2CCCN2C(=O)C2N(C(=O)C(NC(=O)C(C(C)CC)N(C)C)C(C)CC)CCC2OC2=CC=C(OC)C1=C2 BVGNIAWOQSCZOZ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000005827 Phyllostachys nigra Species 0.000 description 1
- 235000010717 Phyllostachys nigra Nutrition 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 108010068736 Pinellia ternata lectin Proteins 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010005109 SALLRSIPA Proteins 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000068081 Sinocalamus beecheyanus Species 0.000 description 1
- 235000005700 Sinocalamus beecheyanus Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 229930185929 Zizyphine Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000019617 piquancy Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- FYSHYFPJBONYCQ-QWHCGFSZSA-N schisanhenol Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-QWHCGFSZSA-N 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- XYSUPNJACJBDTO-UHFFFAOYSA-N zizyphinine Natural products CCC(C)C(NC)C(=O)NC(C(C)CC)C(=O)N1CCC2Oc3ccc(OC)c(C=C/NC(=O)C4CCCN4C(=O)C12)c3 XYSUPNJACJBDTO-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药制剂及其生产方法技术领域。生脉温胆汤新剂型是在传统方剂生脉温胆汤汤剂的剂型基础上,应用现代中医药理论和中药制剂生产的新工艺、新技术和新设备,研制开发的一种既能够充分体现中医药特色,又能有效控制产品质量的生脉温胆汤新剂型口服中药制剂。具体地说是采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材为主要原料,研制开发的一种具有益气养阴、除湿清热作用,用于冠心病、室性早搏、心源性休克等病症的生脉温胆汤新剂型口服中药制剂新产品。生脉温胆汤口服新剂型保持了原有汤剂的固有特色,具有服用剂量少、易服用、剂量准确、质量稳定,适用于商品化大生产。克服了生脉温胆汤汤剂剂型的用量大、携带不方便、不能久贮、无法商品化生产等缺点。
Description
技术领域
本发明属于中药制剂及其生产方法技术领域。
生脉温胆汤新剂型是在传统方剂生脉温胆汤汤剂的剂型基础上,应用现代中医药理论和中药制剂生产的新工艺、新技术和新设备,研制开发的一种既能够充分体现中医药特色,又能有效控制产品质量的生脉温胆汤新剂型口服中药制剂。具体地说是采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材为主要原料,研制开发的一种具有益气养阴、除湿清热作用,用于冠心病、室性早搏、心源性休克等病症的生脉温胆汤新剂型口服中药制剂新产品。
背景技术
冠心病属于中医“胸痹、心痛、厥心痛”等病的范畴。其死亡率占心脏病10%--15%。近年冠心病发病率有上升趋势,而且年龄有所提前。因此,国内外医学家均把本病作为重要的研究内容。中医药在这方面发挥了自己的优势,取得显著疗效[刘沛津,冠心病的中医辨证论治进展,北京中医,1998;5:60-61]。目前对于心血管疾病的治疗,主要是纠正易患因素,调整生活方式及西药治疗。药物治疗主要包括硝酸酯类、钙通道阻滞剂及血管紧张素转换酶抑制剂等,这些药物一般起效快,疗效可靠,但反复使用则会产生耐药性或产生不同程度的不良反应。
生脉温胆汤具有益气养阴、除湿清热作用,临床应用于治疗冠心病、室性早搏、心源性休克等疾病,疗效显著。
王海洲[王海洲;生脉温胆汤治疗冠心病心绞痛235例浙江中西杂志,1991;26(9):392]用生脉温胆汤治疗235例冠心病心绞痛,总有效率为84%。治心绞痛有明显疗效。
吴占光[吴占光,心胆同治治疗冠心病104例疗效观察,实用医学杂志,1998;(14)4:304-305]运用生脉温胆汤化裁,结合自拟宽冠散,对104例冠心病进行治疗观察,获得较为满意效果。
急性病毒性心肌炎,现代医学认为其属免疫功能下降,同时感受病毒所引起。中医将其归于“心悸”、“胸痹”等范畴。李毅等[李毅等,中西药联用治疗急性病毒性心肌炎166例临床观察,江苏中医药,2004:25(5):19-20]观察了生脉温胆汤加减配合西药治疗急性病毒性心肌炎的疗效。采用生脉温胆汤加减配合西药心肌营养剂治疗急性病毒性心肌炎166例,并与西药心肌营养剂辅以抗心律失常药物治疗的83例作对比。结果,治疗组与对照组的主要症状、体征,心电图恢复正常比较有显著性差异(P<0.05)。结论,生脉温胆汤加减配合西药治疗急性病毒性心肌炎疗效较好。
生脉温胆汤治疗冠心病心绞痛疗效显著,在辨证治疗的基础上,还要重视生脉温胆汤新剂型药物制剂的研究,以期获得较为有效的定型的治疗方法和药物,便于临床推广应用。改革生脉温胆汤的剂型、拓宽给药途径,以预防和延缓冠心病的发生,加快其疗效的发挥速度,改变冠心病心绞痛危重症主要依赖西药的局面。
冠心病是整体中的局部病变,既要着眼于局部,也应重视整体。中医治疗冠心病优势在于调节人体的整体功能,注重气血的关系,改善机体对内外环境的变化。掌握通与补,局部与整体的辨证关系,不仅着眼于心脏的局部治疗,而且考虑到整体的改善。因此,生脉温胆汤新剂型中药制剂治疗冠心病有广阔的应用前景。
生脉温胆汤是由生脉散和温胆汤原方组合而成,具有益气养阴、除湿清热之功效。
生脉散出自金元时期李东垣所著的《内外伤辨惑论》,由人参、麦冬、五味子组成,具有益气生津、养阴复脉之功效。现代研究认为,本方具有改善心肌代谢、保护心肌、调节血压、抗休克作用,广泛应用临床治疗多种疾病,特别在治疗心血管疾病方面,取得显著疗效。
温胆汤首见于《备急千金要方》。《三因极一病证方论》中的温胆汤由半夏、陈皮、枳实、竹茹、甘草、茯苓、生姜、大枣组成,有通降胃腑、祛痰化浊、清胆和胃之功效。因其药简效宏,千百年来,救治患者无数,倍受医家所喜爱。历代医家多有延用,时至今日,更是多有发挥。温胆汤有扩张冠状动脉,增加冠脉血流量,改善心肌供血的作用,并能降低交感神经兴奋性,增强机体对缺氧的耐受性,以保护对缺氧敏感的心肌,使冠心病的症状得到缓解。另外,温胆汤还有加强心肌收缩,增加心输出量,调节血压,改善微循环的作用。
生脉温胆汤是我国传统的中药复方汤剂,其汤剂剂型的有效成分、药效、质量控制及作用机制等方面还缺乏科学的量化指标,在安全、有效、稳定等方面还缺乏规范化和标准化,难以取得市场的认同。因此,我们应用现代科学方法和先进中药制剂生产技术进行了生脉温胆汤新剂型的现代生产工艺的研究,开发出既能够体现中医药特色,又能有效控制产品质量的生产工艺方法。
将生脉温胆汤进行剂型改制,研制其口服制剂新剂型是保证产品质量的重要措施。研究生脉温胆汤的有效组分、制备工艺、药效、药理、毒理、剂型等,特别在生脉温胆汤新剂型的提取、分离、纯化、制剂工艺等方面实行标准化,做到定量分析,开发出高效、优质、安全、稳定、服用方便的,具有高技术含量、高附加值的新一代生脉温胆汤新剂型口服中药制剂的新产品,以满足临床需求,具有重要意义。
生脉温胆汤新剂型口服中药制剂,其产品剂量准确、质量稳定,适用于商品化大生产。克服了生脉温胆汤汤剂剂型的用量大、携带不方便、不能久贮、无法商品化生产等缺点。
发明内容
生脉温胆汤新剂型是在传统方剂生脉温胆汤汤剂的剂型基础上,研制开发的一种生脉温胆汤新剂型口服中药制剂新产品。本发明提供了一种具有益气养阴、除湿清热作用的中药口服制剂新产品的生产工艺方法。
本发明的生产工艺技术,能够充分地提取方剂中的药效物质,保持了原方剂特有的疗效与本质;充分体现了中医治病综合成分作用的特点;用单体成分控制制剂质量,制剂产品具有优良的稳定性,适合于工业化大生产。
1、发明目的
本发明的目的之一,在于提供一种服用方便、疗效确切、质量稳定;具有益气养阴、除湿清热作用的生脉温胆汤新剂型口服中药制剂新产品,以克服现有产品领域的缺陷,满足临床需要。
本发明的目的之二,在于提供一种采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材制备的一种生脉温胆汤新剂型口服中药制剂新产品的生产工艺方法。将现代科学技术与传统的中药方剂的优势特色相结合,开发生产的技术先进、质量稳定的生脉温胆汤新剂型口服中药制剂新产品。
本发明的目的之三,在于提供一种能够保证产品质量、适合于工业化大生产的生脉温胆汤新剂型口服中药制剂的生产工艺技术条件,对于提高生脉温胆汤新剂型口服中药制剂产品的质量和实现生产工艺的现代化,具有重要意义。
本发明的目的之四,在于提供一种能够将方剂的药效物质最大限度地提取出来,以保持方剂特有的疗效与本质;充分体现中医治病综合成分作用的特点;用单体成分控制生脉温胆汤新剂型口服中药制剂新产品的生产工艺方法。
2、技术方案
生脉温胆汤是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子组成,原剂型为汤剂,存在使用不便、剂量不准、质量不稳定、无法商品化等问题。
生脉温胆汤新剂型是在生脉温胆汤汤剂剂型的基础上,开发研制的一种生脉温胆汤新剂型中药制剂新产品。具体地说是采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材为主要原料,应用现代制药生产工艺技术研制开发的一种具有益气养阴、除湿清热作用,用于冠心病、室性早搏、心源性休克等病症的生脉温胆汤新剂型中药制剂新产品。
采用均匀设计安排实验,确定最佳的生产工艺条件。在研制过程中,针对不同的配方、制备工艺找出影响因素,选择最佳制剂工艺条件并制订出质量控制标准,使其稳定性处于最佳状态,提高制剂的质量。体现方剂药效物质提取中,发挥活性混合物综合作用的特点。本生产工艺简便,生产周期短,有效成分收率高;增加浸出成分的溶解度,并提高产品的稳定性,有广阔的应用前景。采用高效液相色谱法和薄层色谱扫描法等测定有效成分的含量与定性鉴别,是一种定性鉴别专属性强、简便快速,定量分析准确、重现性好、精密度好的产品质量控制方法。
3、优点及效果
本发明的优点之一是:产品服用方便、具有原方原药、疗效确切、产品质量稳定的优点。
生脉温胆汤新剂型与汤剂剂型比较,由于去除了无效成分及组织物,提高了有效成分的浓度,减少了服用量,而且口感好,易为病人接受。
本发明的优点之二是:生产工艺适合于工业规模化大生产,产品质量稳定。
本发明的一个重要特点是:在于提供一种能够将方剂的药效物质最大限度地提取出来,保持了原方剂特有的疗效与本质;充分体现了中医治病综合成分作用的特点,并且能够用单体成分控制制剂质量的产品质量控制方法。
生脉温胆汤口服新剂型保持了原有汤剂的固有特色,而且具有剂量少、易服用、吸收快、疗效好等优点,本发明是以现代中医药理论和中药制剂生产的新工艺、新技术为依托,开发研制的生脉温胆汤口服新剂型产品,新剂型制剂产品具有优良的稳定性,适合工业化生产。
具体实施方式
生脉温胆汤口服液制剂是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材提取物与适宜的药用辅料合并,制成生脉温胆汤口服液、颗粒剂、丸剂、胶囊剂和片剂。
具体实施是以现代中医药理论为依据,吸取祖国传统医学、现代医学和制药工程技术,并使之有机地结合起来,选取符合《中国药典》2005版一部相关项下要求的半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材,运用现代制剂生产工艺方法研制的一种生脉温胆汤现代中药口服液制剂新产品。
半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材均是《中国药典》收载的常用重要中药材,矫味剂、药用辅料等均符合《中国药典》和国家的相关法规的相关项下的质量标准。
半夏:按照《中国药典》2005年版一部第78页半夏项下检验,应符合规定。半夏为天南星科植物半夏Pinelliaternata(Thunb.)Breit.的干燥块茎,首载于《神农本草经》,已有几千年的用药历史。其性温,味辛,有小毒,归脾、胃、肺经。具有燥湿化痰,降逆止呕,消痞散结之功。用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛,呕吐反胃,胸脘痞满,梅核气等。半夏含有半夏淀粉75.74%、生物碱、β-谷甾醇、葡萄糖苷、胡萝卜苷、草酸钙、半夏蛋白、氨基酸、脂肪酸、无机元素、半夏胰蛋白酶抑制物、胆碱等。其中,氨基酸计16种,有天门冬氨酸、苏氨酸、丝氨酸、谷氨酸、甘氨酸、丙氨酸、精氨酸、赖氨酸等多种脂肪酸如棕榈酸、硬脂酸、油酸、A-亚麻酸、β-亚麻酸等。无机元素计18种,有Al、Fe、Ca、Mg、K、Na、Ti、Mn、P、Zn等;生物碱类如,左旋盐酸麻黄碱等。半夏临床应用非常广泛,具有十分重要的药用价值。
竹茹:按照《中国药典》2005年版一部第93页竹茹项下检验,应符合规定。竹茹为禾本科植物青秆竹Bambusa tuldoioles Munro、大头典竹Sinocalamus beecheyanus(Munro)McClare var.pu bescens P.F.Li或淡竹Phyl2lostachys nigra(lodd)Munro var.henonisStapf的茎秆的干燥中间层,刮成丝条或削成薄片,性微寒,味甘,归肺胃经。常用于因热痰引起的内、儿、妇各科疾病的治疗。竹茹轻可去实,凉能去热,苦能降下,专清痰,为宁神开郁佳品。是临床不可缺少的常用药。竹茹是中医一味传统的清热化痰药,可除烦止吐、通和脉络。竹茹提取物的主要成分为黄酮糖苷和香豆素内酯,它们是有效的自由基清除剂和天然抗氧化剂。
枳实:按照《中国药典》2005年版一部第172页枳实项下检验,应符合规定。枳实为芸香科植物(citrus aurantium L.)酸橙及其栽培变种的干燥未成熟果实或甜橙(C.sinensisosbeck)的干燥幼果。主要含挥发油、辛弗林、N-甲基酪胺、橙皮甙、维生素C及维生素D等。具有破气消积、化痰散痞的作用。用于积滞内停、痞满胀痛、泻痢后重、大便不通、结胸、胃下垂、脱肛、子宫脱垂等症。临床在胃肠道疾病及心血管疾患方面应用较为广泛。
陈皮:按照《中国药典》2005年版一部第132页陈皮项下检验,应符合规定。陈皮为芸香科植物橘Citrus reticulate Blanco及其栽培变种的干燥成熟果皮。味苦、辛,性温,归肺、脾经。具有理气健脾、燥湿化痰之功效。常用于胸脘胀满、食少吐泻、咳嗽多痰。陈皮含挥发油及橙皮苷等有效成分。
甘草:按照《中国药典》2005年版一部第59页甘草项下检验,应符合规定。甘草(Radixglycyrrhizae)为豆科植物甘草(Glycyrrhiza uralensis Fisch)、胀果甘草(Glycyrrhizainflate Bat.)或光果甘草(Glycyrrhiza glabra L.)的干燥根和茎,是极为重要的一味中药材。具有补脾益气、清热解毒、缓急止痛之功效。甘草中主要含有甘草酸(glycyrrhizic acid)、甘草次酸、黄酮、生物碱、氨基酸等化学成分,具有广泛的生理活性。甘草酸是其中最为重要的化学成分(其含量最高可达14%),也是研究得最早、最多的化学成分。用于解毒、消炎、抗过敏、抗溃疡、镇咳、抗肿瘤和防治病毒性肝炎、高血脂症和癌症等疾病。
茯苓:按照《中国药典》2005年版一部第166页茯苓项下检验,应符合规定。茯苓(Poriacocos(Schw.)Wolf)作为传统的中药材,始载于《神农本草经》,被列为上品。味甘淡,性平,有健脾补中,养心安神,利水渗湿的功能。其药用部位为茯苓菌核,含茯苓多糖约为93%。主要化学成分为:多糖、三萜、脂肪酸、甾醇、酶等。茯苓多糖具有促进细胞分裂、补体激活、抗肿瘤、抗癌等生物活性。主治水湿停滞,小便不利,水肿胀满,食少便溏,心悸失眠。
生姜:按照《中国药典》2005年版一部第66页生姜项下检验,应符合规定。生姜是姜科植物姜(Zingiber officinale Rosc.)的新鲜根茎,既是食品,又是临床广泛应用的传统中药。性味辛温,具有散寒解表、温中止吐、回阳通脉、燥湿消痰的功效。可用于风寒表证、咳嗽、肺痿、胃寒呕吐、胸痹和痞证等。民间多用其解鱼蟹毒及生半夏、生南星之毒。生姜主含挥发油和辛辣成份。其芳香和辛辣成份能直接刺激口腔和胃粘膜引起局部血液循环改善,胃液分泌增加,胃酶活性、唾液淀粉酶活性增加,胃肠蠕动增强,有助于提高食欲和促进消化吸收,排出胃肠积气。生姜里含有的辛辣成分被人体吸收后,能抑制体内过氧化脂质的产生,具有抗衰老的功用。
大枣:按照《中国药典》2005年版一部第16页大枣项下检验,应符合规定。大枣为鼠李科植物(Zizp Husjujuba Miil)的成熟果实,大枣作为药用,历史悠久。《伤寒论》、《金匮要略》、《本草纲目》中多有阐述,于《神农本草经》中列为上品,历代本草中均有收载。为补中益气,养血安神,缓和药性的常用中药。大枣含有的酸类有苹果酸、酒石酸、桦木酸等;糖类有多糖及水溶性糖类D-果糖、D-葡萄糖、低聚糖、阿聚糖、半孔荃聚糖、蔗糖等;有机物类有蛋白质、天门冬氨酸、谷氨基酸等多种氨基酸、维生素A、B2、C、P及磷酸腺苷(cAMP);生物碱类有苯基异喹啉型、阿扑啡型、厚阿扑啡型、枣碱及枣宁等;黄酮类化合物有当药黄素(Swertisin)、黄酮-C-葡萄糖苷(Spniosin)、乙酰SpinosinA、B、C等。究最早。大枣具有补血、健脑、抗癌及健脾强身等功效。
人参:按照《中国药典》2005年版一部第7页人参项下检验,应符合规定。人参是中国传统名贵药物,应用于中医临床已有2千多年的历史。有滋补、强壮、抗疲劳、扩血管、益智、抗癌等多方面的作用。人参皂甙是人参的主要有效成分,对人体神经系统、心血管系统、内分泌系统、免疫系统等具有广泛的生物活性,广泛应用于临床实践。近代研究证明人参皂甙对心血管系统的多种疾病如缺血性心脏病、心律失常、心力衰竭等方面均有深远的临床意义,疗效显著,而不良反应少。
麦冬:按照《中国药典》2005年版一部第106页麦冬项下检验,应符合规定。麦冬为百合科植物麦冬的根块,药性甘、微苦、微寒,归胃、肺心经,具有养阴生津、润肺清心之功效。麦冬具有多种药理作用,有很高的药用和保健价值。广泛应用于心脑血管,表现为对中医“血瘀”证的内皮细胞的保护作用,保护心肌缺血和心肌梗塞;免疫调节和肿瘤治疗及糖尿病等。麦冬不但作为单味药对疾病的治疗取得显著成效,而且作为主药与其它中药组成复方药对疾病治疗也取得了一定的发展。
五味子:按照《中国药典》2005年版一部第44页五味子项下检验,应符合规定。五味子为常用中药,商品有北五味子,原植物为五味子(Schisandra chinensis(Turcz.)Baill.)和南五味子,原植物为华中五味子(Schisandra sphenantheraRe2hd.etwils.)。五味子在《神农本草经》中被列为上品,具有收敛、固涩、益气生津、补肾宁心的作用,是中医常用的滋补强壮药。五味子是木兰科北五味子属植物五味子Schsandra chinensis(Turcz.)Bail,以果实入药。本品五味具备,入肺肾经。五味子具有加强和调节心肌细胞、心、肾动脉和能量代谢,改善心肌营养和功能作用。五味子酚有抗氧化作用,可直接清除活性氧自由基。
本发明的目的是这样实现的:
生脉温胆汤新剂型是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材,加水煎煮、合并煎液、浓缩、调剂、干燥等,再加入适宜的药用辅料,制成生脉温胆汤口服液、颗粒剂、胶囊剂、丸剂和片剂。
1、生脉温胆汤口服液及其生产方法:
生脉温胆汤口服液及其生产方法,其特征在于:是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材提取物,加入适宜的药用辅料制成生脉温胆汤口服液制剂。
生脉温胆汤口服液及其生产方法,其特征在于:药材的重量百分比含量为:4-14%半夏、4-14%竹茹、4-14%枳实、7-21%陈皮、2-7%甘草、4-11%茯苓、4-15%人参、4-11%生姜、2-7%大枣、7-21%麦冬和4-14%五味子等共计十一味。
生脉温胆汤口服液及其生产方法,其特征在于:将药材加水煎煮、合并煎液、浓缩等,再与适量的药用辅料混匀,调剂,制成生脉温胆汤口服液制剂的过程。
生脉温胆汤口服液及其生产方法,其特征在于:是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味药材提取物、矫味剂、防腐剂和水等组成。
生脉温胆汤口服液及其生产方法,其特征在于:是采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味药材提取物,添加矫味剂、防腐剂等,加水调剂;经过罐装、灭菌、检验、包装等生产工艺制备而成。
生脉温胆汤口服液及其生产方法,其特征在于:药材提取液、矫味剂、防腐剂和水的重量百分比含量为药材提取物2-99%、矫味剂0.1-15%、防腐剂0.01-1%和水50-98%,生脉温胆汤口服液每ml液体中相当于含有0.2-12克的生药量。
将生脉温胆汤提取物与适宜的药用辅料制成生脉温胆汤口服液,其特征是药用辅料包括矫味剂、防腐剂;矫味剂是蔗糖、糖精钠、环己基氨基磺酸钠、甜菊糖苷、天门冬酰苯丙氨酸甲酯、乙酰磺胺酸钾、薄荷油(醇)中的一种或二种;防腐剂是丁香油、山梨醇、山梨酸甲酯、苯甲酸类、尼泊金类中的一种。
生脉温胆汤口服液及其生产方法,其特征在于:采取如下步骤的生产工艺:先将药材浸泡,再用水煎煮2-3次;或者,用pH1-2的水作第一煎,pH8-10的水作第二、三煎,煎煮;合并煎液,过滤,除去残渣,滤液减压浓缩;加入乙醇,静置,滤除杂质,回收乙醇,备用;或者,将提取滤液用分离机离心,取上清液,加水调剂,经超滤器超滤,备用;加入矫味剂等,搅拌,混合;加水调剂至制备量;经灭菌、罐装、检验、包装等工艺,即得生脉温胆汤口服液。
2、生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法:
生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:制备颗粒剂或丸剂或胶囊剂或片剂时,所用的药用辅料,包括稀释剂、粘合剂、润滑剂;稀释剂包括淀粉、乳糖、糊精、微晶纤维素、硬脂酸钙中的一种或几种;粘合剂包括水、高分子材料、乙醇中的一种或几种;润滑剂包括硬脂酸镁、滑石粉、硬脂酸中的一种或几种。
生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:制备颗粒剂或丸剂或胶囊剂或片剂时,将药材加水煎煮、合并煎液、浓缩、干燥后,与适量的药用辅料混匀,加入粘合剂等制成软材,用制粒机制成颗粒,干燥、整粒,即得颗粒剂;或经过制丸机制成丸剂;或经过硬胶囊填充机制成胶囊剂;或经过压片机制成片剂。
生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂的每克颗粒中,相当于含有1-35克的生药量。
本发明的生脉温胆汤新剂型产品,按照上述方法制备,其最佳工艺和组分由下列实施例给出,但本发明的保护范围不局限于此。
实施例:
实施例1(生脉温胆汤口服液):
取处方量的12公斤半夏、12公斤竹茹、12公斤枳实、18公斤陈皮、6公斤甘草、10公斤茯苓、12公斤人参、10公斤生姜、6公斤大枣、18公斤麦冬和12公斤五味子等十一味药材,加水浸泡0.5小时;再加水煎煮2次;第1次2.5h,第2次1h;合并煎液,滤过,滤液减压浓缩,加95%乙醇使含醇量达65%,静置48h,回收乙醇,加蒸馏水至总量20L,搅匀,滤过,调pH至6.5,灌封,灭菌,即得。
实施例2(生脉温胆汤口服液):
取处方量的各种药材,加水煎煮2次。第1次2.5h,第2次1h。合并煎液,滤过,滤液减压浓缩,加95%乙醇使含醇量达65%,静置48h,回收乙醇,加蒸馏水至总量1000L,搅匀,冷藏24h,滤过,调pH至6.5,灌封,灭菌,即得。
实施例3(生脉温胆汤口服液):
取处方量的各种药材,第一次煎煮加pH1水煎煮1h,第二次煎煮加pH9水煎煮2h;合并煎液,滤过,滤液减压浓缩至1∶2,加95%乙醇使含醇量达60%,静置48h,回收乙醇,加蒸馏水至总量,搅匀,冷藏24h,滤过,调pH值,灌封,灭菌,即得。
实施例4(生脉温胆汤口服液):
取处方量的各种药材,第一次煎煮加pH2水煎煮1h,第二次煎煮加pH9水煎煮2h;合并煎液,滤过,滤液减压浓缩至1∶1,用管式分离机离心(15000rmin),取上清液,加蒸馏水至1000ml,经超滤器超滤,超滤压力0.2MPa,超滤液灌封,灭菌,即得。
实施例5(生脉温胆汤口服液):
先将药材浸泡0.5小时,再用水煎煮3次;用pH2的水作第一煎,pH8的水作第二、三煎,煎煮;合并煎液,过滤,除去残渣;将提取滤液用分离机离心,取上清液,加水调剂,经超滤器超滤,备用;加入矫味剂等,搅拌,混合;加水调剂至制备量;经灭菌、罐装、检验、包装等工艺,即得生脉温胆汤口服液。
实施例6(生脉温胆汤颗粒剂):按重量百分比含量为:
生脉温胆汤提取物 :16-95%
淀粉 :1-45%
糊精 :5-55%
蔗糖 :5-55%
35%乙醇 :适量。
实施例7(生脉温胆汤丸剂):按重量百分比含量为:
生脉温胆汤提取物 :15-95%
淀粉 :5-55%
蜂蜜 :5-25%
糊精 :5-40%
硬脂酸 :1-15%
水 :适量。
实施例8(生脉温胆汤胶囊剂):按重量百分比含量为:
生脉温胆汤提取物 :10-95%
淀粉 :5-55%
硬脂酸镁 :0.001-0.5%
水 :适量。
实施例9(生脉温胆汤片剂):按重量百分比含量为:
生脉温胆汤提取物 :25-95%
淀粉 :5-45%
糊精 :5-55%
滑石粉 :0.1-3%
45%乙醇 :适量。
实施例的制备工艺与处方仅为了对本发明作进一步的说明,而本发明产品的保护范围不受该最佳工艺与处方局限的限制。
Claims (8)
1.生脉温胆汤新剂型及其生产方法,其特征在于:是由半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材,加水煎煮、合并煎液、浓缩、调剂、干燥等,再加入适宜的药用辅料,制成生脉温胆汤口服液、颗粒剂、胶囊剂、丸剂和片剂。
2.根据权利要求1所述的生脉温胆汤新剂型及其生产方法,其特征在于:在制备生脉温胆汤口服液时,是采用半夏、生姜、竹茹、枳实、陈皮、甘草、茯苓、大枣、人参、麦冬和五味子等十一味中药材的提取物,添加矫味剂、防腐剂等,加水调剂;经过罐装、灭菌、检验、包装等生产工艺制备而成。
3.根据权利要求1、2所述的生脉温胆汤新剂型及其生产方法,其特征在于:在制备生脉温胆汤口服液时,药材提取液、矫味剂、防腐剂和水的重量百分比含量为药材提取物2-99%、矫味剂0.1-15%、防腐剂0.01-1%和水50-98%,生脉温胆汤口服液每ml液体中相当于含有0.2-12克的生药量。
4.根据权利要求1、2所述的生脉温胆汤新剂型及其生产方法,其特征在于:将生脉温胆汤提取物与适宜的药用辅料制成生脉温胆汤口服液时,其药用辅料包括矫味剂、防腐剂;矫味剂是蔗糖、糖精钠、环己基氨基磺酸钠、甜菊糖苷、天门冬酰苯丙氨酸甲酯、乙酰磺胺酸钾、薄荷油(醇)中的一种或二种;防腐剂是丁香油、山梨醇、山梨酸甲酯、苯甲酸类、尼泊金类中的一种。
5.根据权利要求1所述的生脉温胆汤新剂型及其生产方法,其特征在于:在制备生脉温胆汤口服液时,采取如下步骤的生产工艺:先将药材浸泡,再用水煎煮2-3次;或者,用pH1-2的水作第一煎,pH8-10的水作第二、三煎,煎煮;合并煎液,过滤,除去残渣,滤液减压浓缩;加入乙醇,静置,滤除杂质,回收乙醇,备用;或者,将提取滤液用分离机离心,取上清液,加水调剂,经超滤器超滤,备用;加入矫味剂等,搅拌,混合;加水调剂至制备量;经灭菌、罐装、检验、包装等工艺,即得生脉温胆汤口服液。
6.根据权利要求1所述的生脉温胆汤新剂型及其生产方法,其特征在于:制备生脉温胆汤颗粒剂或丸剂或胶囊剂或片剂时,将药材加水煎煮、合并煎液、浓缩、干燥后,与适量的药用辅料混匀,加入粘合剂等制成软材,用制粒机制成颗粒,干燥、整粒,即得颗粒剂;或经过制丸机制成丸剂;或经过硬胶囊填充机制成胶囊剂;或经过压片机制成片剂。
7.根据权利要求1、6所述的生脉温胆汤新剂型及其生产方法,其特征在于:制备生脉温胆汤颗粒剂或丸剂或胶囊剂或片剂时,所用的药用辅料,包括稀释剂、粘合剂、润滑剂;稀释剂包括淀粉、乳糖、糊精、微晶纤维素、硬脂酸钙中的一种或几种;粘合剂包括水、高分子材料、乙醇中的一种或几种;润滑剂包括硬脂酸镁、滑石粉、硬脂酸中的一种或几种。
8.根据权利要求1、6所述的生脉温胆汤新剂型及其生产方法,其特征在于:制备生脉温胆汤颗粒剂、丸剂、胶囊剂和片剂的每克颗粒中,相当于含有1-35克的生药量。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101231244A CN101172155A (zh) | 2006-11-01 | 2006-11-01 | 生脉温胆汤新剂型及其生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101231244A CN101172155A (zh) | 2006-11-01 | 2006-11-01 | 生脉温胆汤新剂型及其生产方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101172155A true CN101172155A (zh) | 2008-05-07 |
Family
ID=39421044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101231244A Pending CN101172155A (zh) | 2006-11-01 | 2006-11-01 | 生脉温胆汤新剂型及其生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101172155A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104286245A (zh) * | 2014-08-29 | 2015-01-21 | 安徽霍山县吉元竹纤维有限公司 | 一种竹茹养生茶 |
| CN115068551A (zh) * | 2015-05-13 | 2022-09-20 | 陕西摩美得气血和制药有限公司 | 一种抗心律失常的中药组合物及其应用 |
| US11718594B2 (en) | 2016-09-21 | 2023-08-08 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11724993B2 (en) | 2016-09-21 | 2023-08-15 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11724994B2 (en) | 2016-09-21 | 2023-08-15 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11731948B2 (en) | 2016-09-21 | 2023-08-22 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
-
2006
- 2006-11-01 CN CNA2006101231244A patent/CN101172155A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104286245A (zh) * | 2014-08-29 | 2015-01-21 | 安徽霍山县吉元竹纤维有限公司 | 一种竹茹养生茶 |
| CN115068551A (zh) * | 2015-05-13 | 2022-09-20 | 陕西摩美得气血和制药有限公司 | 一种抗心律失常的中药组合物及其应用 |
| US11718594B2 (en) | 2016-09-21 | 2023-08-08 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11724993B2 (en) | 2016-09-21 | 2023-08-15 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11724994B2 (en) | 2016-09-21 | 2023-08-15 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
| US11731948B2 (en) | 2016-09-21 | 2023-08-22 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078402B (zh) | 治疗高血压、高血脂和高血糖的中药组合物 | |
| CN101239112B (zh) | 调节血脂的中药组合物及其制备方法 | |
| CN103041118A (zh) | 一种具有降血糖降血脂作用的组合物 | |
| CN102742833B (zh) | 一种保护心脏的食疗产品及其制备方法 | |
| CN103719492A (zh) | 一种绞股蓝护肝养肝保健茶及其制备方法 | |
| CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
| CN101011561B (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
| CN101543248B (zh) | 一种特别适合“三高一酸”人群饮用的凉茶及其制备方法 | |
| CN111110735A (zh) | 一种降脂的药物组合物、制备方法及应用 | |
| CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
| CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
| CN104173585A (zh) | 一种含红景天的适应原制剂及其制备方法 | |
| CN107596014A (zh) | 一种降血糖、血压和血脂的药物及其制备方法 | |
| CN101011562A (zh) | 参芪温胆汤新剂型及其生产方法 | |
| CN106109521A (zh) | 一种三七口服液 | |
| CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
| CN101982194A (zh) | 一种治疗湿热困脾型糖尿病的黄连复方制剂 | |
| CN102228596B (zh) | 一种药物组合物及制剂及在治疗冠心病、心绞痛中的应用 | |
| CN105168581A (zh) | 一种中药组合物用于制备治疗糖尿病肾病药物中的用途 | |
| CN105169187B (zh) | 一种组合物及其应用,其制备方法以及含有该组合物的药物、食品 | |
| KR20060030575A (ko) | 생약추출물을 함유하는 갑상선기능 항진증의 예방 및치료용 약학 조성물 | |
| CN119896709B (zh) | 一种用于糖尿病肾病的中药组合物及其制备方法和应用 | |
| CN112823807A (zh) | 一种阿胶人参膏及其制备方法 | |
| CN104547800A (zh) | 一种中药制剂在制备治疗酒精性脂肪肝药物中的用途 | |
| CN103330209B (zh) | 一种辅助降血糖的纯中药保健食品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080507 |